Conv. Plasma
Nigella Sativa
Peg.. Lambda

All convalescent plasma..
Meta analysis
Home COVID-19 treatment researchConvalescent PlasmaConv. Plasma (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality -1% Improvement Relative Risk Ventilation 67% Progression 14% Progression (b) 42% Hospitalization 39% Hospitalization time -50% Recovery -1% Recovery time -8% Conv. Plasma  Gharbharan et al.  EARLY TREATMENT  DB RCT Is early treatment with convalescent plasma beneficial for COVID-19? Double-blind RCT 416 patients in Netherlands (Nov 2020 - Jul 2021) Lower progression (p=0.42) and hospitalization (p=0.22), not sig. Gharbharan et al., Clinical Microbiolo.., Aug 2022 Favors conv. plasma Favors control

Outpatient convalescent plasma therapy for high-risk patients with early COVID-19. A randomized placebo-controlled trial

Gharbharan et al., Clinical Microbiology and Infection, doi:10.1016/j.cmi.2022.08.005, NCT04589949
Aug 2022  
  Source   PDF   All Studies   Meta AnalysisMeta
RCT 416 outpatients in the Netherlands, showing no significant difference with convalesent plasma treatment. Hospitalization was lower, and improved results were seen with ≤5 days of symptoms, without statistical significance.
risk of death, 1.0% higher, RR 1.01, p = 1.00, treatment 1 of 207 (0.5%), control 1 of 209 (0.5%), day 28.
risk of mechanical ventilation, 66.6% lower, RR 0.33, p = 1.00, treatment 0 of 207 (0.0%), control 1 of 209 (0.5%), NNT 209, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 28.
risk of progression, 14.0% lower, OR 0.86, p = 0.42, treatment 207, control 209, adjusted per study, improved severity score, RR approximated with OR.
risk of progression, 42.0% lower, OR 0.58, p = 0.06, treatment 123, control 103, adjusted per study, improved severity score, ≤5 days, RR approximated with OR.
risk of hospitalization, 39.0% lower, HR 0.61, p = 0.22, treatment 10 of 207 (4.8%), control 18 of 209 (8.6%), NNT 26, adjusted per study, day 28.
hospitalization time, 50.0% higher, relative time 1.50, p = 0.56, treatment 207, control 209.
risk of no recovery, 1.0% higher, RR 1.01, p = 0.92, treatment 137 of 207 (66.2%), control 137 of 209 (65.6%), continued COVID-19 symptoms, day 27.
recovery time, 8.3% higher, relative time 1.08, p = 0.99, treatment 207, control 209.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Gharbharan et al., 23 Aug 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Netherlands, peer-reviewed, 59 authors, study period November 2020 - July 2021, average treatment delay 5.0 days, trial NCT04589949 (history).
All Studies   All Outcomes   Submit Updates or Corrections
This PaperConv. PlasmaAll
Outpatient convalescent plasma therapy for high-risk patients with early COVID-19: a randomized placebo-controlled trial
Arvind Gharbharan, Carlijn Jordans, Lisa Zwaginga, Grigorios Papageorgiou, Nan Van Geloven, Peter Van Wijngaarden, Jan Den Hollander, Faiz Karim, Elena Van Leeuwen-Segarceanu, Robert Soetekouw, Jolanda Lammers, Douwe Postma, Linda Kampschreur, Geert Groeneveld, Francis Swaneveld, C Ellen Van Der Schoot, Hannelore Götz, Bart Haagmans, Marion Koopmans, Susanne Bogers, Corine Geurtsvankessel, Jaap Jan Zwaginga, Casper Rokx, Bart Rijnders
Clinical Microbiology and Infection, doi:10.1016/j.cmi.2022.08.005
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Conflicts of interest: We declare no conflicts of interest. Acknowledgments: The
Alemany, Millat-Martinez, Corbacho-Monné, Malchair, Ouchi et al., High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial, The Lancet Respiratory Medicine
Bernal, Da Silva, Musungaie, Kovalchuk, Gonzalez et al., Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients, New England Journal of Medicine
Dougan, Nirula, Azizad, Mocherla, Gottlieb et al., Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19, New England Journal of Medicine
Gharbharan, Jordans, Geurtsvankessel, Hollander, Karim et al., Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection, Nature Communications
Gupta, Gonzalez-Rojas, Juarez, Casal, Moya et al., Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab, New England Journal of Medicine
Hammond, Leister-Tebbe, Gardner, Abreu, Wisemandle, Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19, New England Journal of Medicine
Huygens, Hofsink, Nijhof, Goorhuis, Kater et al., immunocompromised patients with COVID-19: a randomised, controlled, double-blind, phase 3 trial
Huygens, Munnink, Gharbharan, Koopmans, Rijnders, High incidence of sotrovimab resistance and viral persistence after treatment of immunocompromised patients infected with the SARS-CoV-2 Omicron variant, medRxiv
Korley, Durkalski-Mauldin, Yeatts, Schulman, Davenport et al., Early Convalescent Plasma for High-Risk Outpatients with Covid-19, New England Journal of Medicine
Kumar, Hu, Samson, Ferreira, Victoria et al., Neutralization against Omicron variant in transplant recipients after three doses of mRNA vaccine, American Journal of Transplantation
Libster, Marc, Wappner, Coviello, Bianchi et al., Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults, New England Journal of Medicine
Malahe, Hoek, Dalm, Broers, Den Hoed et al., Clinical characteristics and outcome of immunocompromised patients with COVID-19 caused by the Omicron variant: a prospective observational study, medRxiv
Petrilli, Jones, Yang, Rajagopalan, Donnell et al., Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study, BMJ
Piechotta, Iannizzi, Chai, Valk, Kimber et al., Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review, Cochrane Database of Systematic Reviews
Rijnders, Huygens, Mitjà, Evidence-based dosing of convalescent plasma for COVID-19 in future trials, Clinical Microbiology and Infection
Rockwood, Theou, Using the Clinical Frailty Scale in Allocating Scarce Health Care Resources, Can Geriatr J
Sullivan, Gebo, Shoham, Bloch, Lau et al., Early Outpatient Treatment for Covid-19 with Convalescent Plasma, New England Journal of Medicine
Takashita, Kinoshita, Yamayoshi, Sakai-Tagawa, Fujisaki et al., Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2, New England Journal of Medicine
Vanblargan, Errico, Halfmann, Zost, Crowe et al., An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies, Nature Medicine
Weinreich, Sivapalasingam, Norton, Ali, Gao et al., None
Williamson, Walker, Bhaskaran, Bacon, Bates et al., Factors associated with COVID-19-related death using OpenSAFELY, Nature
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop